Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus Fulvestrant in ER+/HER2- Advanced Breast Cancer
NCT03584009Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of venetoclax in breast cancer, sponsored by Roche. Started Sep 2018; status: terminated.
02
Drugs
venetoclax
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03584009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03584009.